Glythera

Glythera Limited is a biotechnology company specializing in the development of platform technologies for next generation biotherapeutics. We have 2 core programmes:

- PermaLinkâ„¢ - a novel, stable, highly cysteine-specific conjugation platform for antibody drug conjugates (ADCs). PermaLinkâ„¢ is associated with enhanced anti-tumour activity in vivo vs maleimide in comparative ADC models. It is suitable for cleavable and non-cleavable systems

- PermaCarbâ„¢ - a novel sialylation correction platform which can (i) improve bioavailability & enhance product performance and (ii) remove the issue of sialic acid contamination. It is particularly appropriate for the development of biobetters and biosimilars. PermaCarbâ„¢ has been validated vs several biotherapeutics, including FSH and etanercept

Based in the NE of England, Glythera has dedicated bioprocessing and chemistry laboratories enabling us to conduct in-house evaluations for our partners to progress applications of PermaLinkâ„¢ and PermaCarbâ„¢ technologies.

We are seeking license collaborations for PermaLinkâ„¢ and out-license partners for PermaCarbâ„¢

		From	To	From	To	From	To
Monday	Open
Tuesday	Open
Wednesday	Open
Thursday	Open
Friday	Open
Saturday	Closed
Sunday	Open